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Surrtmary 
We have established long-term cultures of several cell lines stably and uniformly expressing human 
immunodeliciency virus type 1 (HIV-1) in order to (a) identify naturally processed HIV-1 peptides 
recognized by cytotoxic T lymphocytes (CTL) from HIV-l-seropositive  individuals and (b) consider 
the hypothesis that naturally occurring epitope densities on HIV-infected cells may limit their 
lysis by  CTL.  Each  of two  A2-restricted  CD8 +  CTL  specific for  HIV-1  gag  or  reverse 
transcriptase (RT) recognized a single naturally pr6cessed HIV-1 peptide in trifluoroacetic  acid 
(TFA) extracts of infected cells: gag 77-85 (SLYNTVATL) or RT 476-484 (ILKEPVHGV). Both 
processed peptides match the synthetic peptides that are optimally active in cytotoxicity assays 
and have the consensus motif described for A2-associated peptides. Their abundances were 
and =12 molecules per infected Jurkat-A2 cell, respectivdy. Other synthetic HIV-1 peptides active 
at subnanomolar concentrations were not present in infected cells. Except for the antigen processing 
mutant line T2, HIV-infected HLA-A2 + cell lines were specifically lysed by both A2-restricted 
CTL, although infected Jurkat-A2 cells were lysed more poorly by RT-specific CTL than by 
gag-specific CTL, suggesting that low cell surface density of a natural peptide may limit the 
effectiveness of some HIV-specific CTL despite their vigorous activity against synthetic peptide- 
treated target cells. 
M 
HC-restricted CTL play a central role in immune re- 
sponses  against  many viruses  by destroying virus- 
infected cells (1). Unlike antibodies,  CD8 + CTL recognize 
conserved sequences from intracellular viral proteins in addi- 
tion to sequences from virus-encoded cell surface glycopro- 
teins  (2).  CD8 +  CTL  specific for diverse HIV products 
(e.g., gag, pol, nef, env) appear within 1-2 wk of infection, 
and the importance of these CTL is suggested by their un- 
usually high frequencies: they can often be detected in freshly 
isolated PBMC without the in vitro antigenic stimulation 
usually required to demonstrate CTL activity in other viral 
infections  (3-14). 
It has been proposed that the CD8 + CTL response to 
HIV is one of the main factors contributing to a long asymp- 
tomatic period in infected individuals (15, 16). Recent studies 
documenting HIV-specific T cells in HIV-exposed but unin- 
fected individuals further support a role for these cells in con- 
trolling infection (17-19). Yet CTL usually do not succeed 
in eradicating HIV (20, 21). Two possible mechanisms for 
this failure are viral mutation leading to escape from CTL 
recognition (22-25) and altered lymphokine production sec- 
ondary to depletion of CD4 + T  cells. Another possibility 
is that the density of many HIV epitopes  (i.e., particular 
peptide-MHC comple~s) on infected cells is too low to trigger 
effective lysis of these cells by mature CD8 + CTL in vivo. 
In considering this third possibility, it is important to dis- 
tingnish between acute infection by viruses such as influenza 
or vaccinia, in which viral genes are overexpressed at the ex- 
pense of host cell protein synthesis, and chronic infection by 
HIV, in which cells continue to express their normal com- 
plement of self proteins (as evidenced by their ability to grow 
and proliferate for long periods; see below). In the latter case, 
HIV-derived peptides must compete with a much larger excess 
of host  cell  peptides  for  presentation  by  class  I  MHC 
(MHC-I) 1 proteins  to  CD8 +  T  cells.  Can  a  sufficient 
1  Abbreviations used in this f, per: MHC-I,  class I  MHC;  RT,  reverse 
transcriptase;  SDs0, pepfide concentration that sensitizes target cells for 
half-maximal lysis; TFA, trifluoroacetic add; VSV, vesica~ stomatitis 
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sites in order to render infected cells good targets for destruc- 
tion by CTL? The presence of a vigorous and spedfic CTL 
response  in HIV infection implies that the density of HIV 
epitopes  is  suffldent  to  stimulate  the  differentiation  of 
CD8 + precursor T cells into mature CTL (at least on those 
cells involved in CTL induction). However, it remains un- 
clear whether the number of specific peptide--MHC-I com- 
plexes on most HIV-infected cells (i.e., CD4 + T cells, mac- 
rophages) is adequate for efiident killing of these cells by 
mature CD8 + CTL. 
The density of an HIV epitope on infected cells cannot 
be measured without first knowing the precise  identity of 
the HIV peptide involved. Prior work characterizing HIV 
epitopes has relied on vacania recombinants (26)  and syn- 
thetic peptides up to =25 amino adds in length (27,  28). 
However, the peptides produced by cellular antigen processing 
pathways may or may not be identical to the synthetic pep- 
tides used in target cell sensitization assays (29),  and so the 
exact identities ofHIV epitopes in infected cells are not known. 
To reveal both the identities and abundances ofHIV peptides 
presented endogenously  by MI-IC-I molecules, as well as other 
properties  such as  their  MHC binding a~nities and im- 
munogenidties, we have established  an assay system based 
on several newly developed cell lines that stably and uniformly 
express HIV-1 and CTL obtained from HIV-seropositive in- 
dividuals. 
Materials and Methods 
Cells.  The following human cell lines were used for transfec- 
tions and infections (MHC-I molecules expressed by each cell are 
in parentheses):  Jurkat (HLA-A9,  A25, B7, B41); Jurkat stably  trans- 
fected with the gene for HLA-A2 and here designated  JA2 (kindly 
supplied by Dr. Linda Sherman, The Scripps Research Institute, 
LaJolla, CA) (30); H9 (HLA-A1,  Bw62, Cw6); MOLT4; the TxB 
hybridoma T1 (I-ILA-A2, BS); the antigen processing mutant T2 
derived from T1 (both kindly provided  by Dr. Peter Cresswell, Yale 
University, New Haven, CT) (31); the EBV-transformed  B cell line 
JY (HLA-A2, BT, Cw7); and the promonocytic cell line U937. 
An cell  lines  were grown in "K" medium (ILPMi  1640 supplemented 
with 10% heat-inactivated FCS, 10 mM Hepes, 2 mM glutamine, 
100 U/m1 penicillin, 100/~g/ml streptomycin, and 50 ~tM 2-ME). 
CTL were derived  from PBMC obtained from asymptomatic HIV- 
1-seropositive subjects and maintained as described (32, 33). 
Transfection with Cloned HIV-1 DNA.  The establishment of  cell 
lines stably expressing  HIV-1 proviral DNA was achieved  by trans- 
fection with plasmid vectors RTneo or RThyg, modifications of 
pHXB2gpt (34) in which selectable marker genes conferring resis- 
tance to G418 or hygromycin  B, respectively,  were inserted in place 
of a 255 bp fragment located at the 5' end of the nef gene (35). 
The resulting plasmid DNA, which includes the entire HIV-1 ge- 
nome except for nef, was purified and linearized by digestion with 
XbaI, and transfections were carried out by electroporation as de- 
scribed (35). 107 cells (Jurkat, JA2, Hg, MOLT4, T1, T2, JY, or 
U937) were washed and resuspended  in 0.4 nd cold PBS in 0.4-cm 
dectroporation cuvettes, mixed with 20/zg linearized  plasmid  DNA, 
placed on ice for 5 min, subjected to a single pulse of 250 V, 960 
gtF (Bio-Rad apparatus; Bio-Rad Laboratories, Hercules, CA), and 
returned to ice for 10 min. Measured time constants were 30-40 
ms. Cells were then washed and resuspended in K medium for in- 
cubation at 37~  in 5% CO2. 
After 48 h, an aliquot of 200 ~tl from each culture supernatant 
was assayed  for HIV-1 production by p24 ELISA (DuPont NEN, 
Boston, MA). Depending on the phsmid used, K7neo or RThyg, 
cells were selected  with 0.5 mg/ml G418 (GIBCO BRL, Gaithers- 
burg, MD) or hygromycin B (Calbiochem-Novabiochem  Corp., 
San Diego, CA), a concentration shown to result in the death of 
over 50% of  untransfected cells  within 6 d;JA2 cells already  under 
selection with 250 ~tg/ml G418 for A2 expression, were transfected 
only with K7hyg and subjected  to dual selection.  After several  weeks 
of stable growth and evidence of HIV expression in all cells by 
immunofluorescence (see below), cells were maintained and ex- 
panded in 162 cm  2 cell culture flasks (Costar Corp., Cambridge, 
MA) in the presence of 0.25 rag/m1 G418 and/or hygromycin B. 
HIV-expressing  cell  lines  were named  according  to the phsmid vector 
used: JA2/R7hyg, H9/R7neo, H9/R.7hyg, etc. 
Immunofluorescence Microscopy and Flow Cytometry.  To test for 
HIV expression, acetone-fixed  cells  were stained with a mouse anti- 
p24 monoclonal antibody for 30 rain at room temperature (36). 
After the slides were washed with PBS, cells were incubated with 
the F(ab')z fragment of FITC-conjugated goat anti-mouse  IgG 
(Cappel Laboratories, Durham, NC or Sigma Chemical Co., St. 
Louis, MO) for 30 min at room temperature in the dark. Cells 
were then washed, counterstained with 0.5% Evans blue dye in 
PBS (Sigma Chemical Co.) for 10 rain, washed again, and exam- 
ined under a fluorescent microscope. For purposes of visualizing 
all cells and calculating the proportion of  cells expressing HIV, cells 
that had been stained with anti-p24 and FITC-conjugated anti- 
bodies were also examined by phase contrast. 
All cells were checked to confirm A2 status before transfection 
and, for A2 + cells, several weeks after being grown under sdec- 
tion for HIV expression. 5  x  10  s cells were stained with 1 gig 
of the anti-A2 monoclonal antibody PA2.1 and with 5 ~tg of the 
F(ab')z fragment of FITC-conjugated goat anti-mouse IgG (Pierce 
Chemical Co., Rockford, IL) and were then analyzed  on an EPICS 
C cytofluorimeter (Coulter Corp., Hialeah, FL) or by fluorescence 
microscopy (for HIV + cells). CD4 expression before transfection 
was also determined using an anti-human CD4 monoclonal anti- 
body (Becton Dickinson & Co., Mountain View, CA). 
Peptide Synthe~  and  Chromatography.  All peptides were synthe- 
sized by standard t-Boc chemistry on a peptide synthesizer (modal 
430A; Applied Biosystems,  Inc., Foster City, CA), analyzed  by re- 
verse phase HPLC and amino acid analysis,  and found to be highly 
pure. Peptides were named according to the protein source (gag 
or reverse transcriptase [KT]), the first and last amino acid residues, 
and the peptide length,  e.g., gag-SL9 =  SLYNTVATL  and KT- 
IV9 = ILKEFVHGV. Peptide concentrations measured by Micro 
BCA Assay (Pierce Chemical Co.) ranged from 10 to 100% of the 
concentrations calculated from dry weights; for peptides geg-SL9 
and RT-IV9, precise concentrations were determined by quantita- 
tive amino acid analysis. HPLC separations of synthetic peptides 
were performed using a 4.6  x 250 mm C18 reverse phase column 
(model 218TP104; VYDAC, Hesperia, CA). The gag peptides were 
separated on a gradient of  0.25% B/min at a flow rate of 1 ml/min, 
with A ,* 0.1% trifluoroacetic acid (TFA) (Pierce Chemical Co.) 
in H20 and B = 0.1% TFA in isopropanol, and the KT peptides 
were separated  on a gradient of 1% B/min at a flow rate of 1 rnl/min, 
with  A  =  0.1%  TFA  in  HzO  and  B  =  0.085%  TFA  in 
acetonitrile. 
NaturalPeptideExtraction andFractionation.  Cultured cells  were 
harvested by centrifugation, washed with cold PBS, and stored in 
batches of 109 at  -70~  Cells were lysed by adding 15 ml 1% 
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pH below 2), and douncing with 50 strokes. The material  was trans- 
ferred to a Centriprep 10 r  device (Amicon Corp., 
Beverly, MA) and subjected to centrifugation at 2,600 g for several 
hours at 4~  (37). The ultrafiltrate (molecular mass <10 kD) was 
removed (>12 nil), an equal volume of 1% TFA was added to the 
retentate, and centrifugation was repeated twice in order to max- 
imize the recovery  of extracted peptides. Pooled  filtrates were dried 
by lyophillzation and redissolved in 0.1% TFA for fractionation 
by HPLC using the conditions described above for either the gag 
or the RT peptides. 40 fractions were coUected  at 1 min intervals 
in presiliconized microfuge tubes, dried by SpeedVac (Savant In- 
struments, Inc., Farmingdale, NY), and redissolved  in H20 with 
vortexing. 
Cytotaxicity  Assa~  CTL assays  were performed  as desm~,ed  (38), 
using SlCr-labded 115EBV cells (an autologous EBV-transformed 
B cell line) for CTL line 115Ip, or SlCr-labeled  JY ceils for CTL 
clone 68A62 when testing synthetic peptides or HPLC fractions. 
Results 
Establishment o/Long-term Cell Lines Stabl  7 and Uniformly 
Expressing HIV-1.  Several  human ceil lines were chosen for 
transfection with HIV-1 proviral DNA linked to a drug re- 
sistance  gene,  including T  cells  (Jurkat,  JA2,  Hg,  and 
MOLT-4), a TxB hybrid (T1) and its derivative antigen pro- 
cessing mutant cell line (T2), an EBV-transformed B ceil line 
0Y), and a promonocytic call line (U937). 2 d after transfec- 
tion of each line by dectroporation with plasmid lk7neo or 
RThyg (35), cell culture supernatants were shown to contain 
the HIV-1 p24 core antigen by ELISA. Selection was initi- 
ated either at this time or 3 wk later in order to permit infec- 
tion of untransfected ceils with virus produced by success- 
fully transfected ceils in the same culture; such infected (as 
opposed to transfeeted) cells also acquired the drug resistance 
gene. For convenience, HIV-expressing cell lines are referred 
to as HIV-infected even though they may indude both trans- 
fected and infected ceils. After several weeks during which 
fresh medium was supplied two to three times per week, all 
eight ceil cultures were found to be 100% HIV + by p24 im- 
munofluorescence (Fig.  1). 
JA2/R7hyg (JA2 cells transfected  with plasmid R7hyg) 
and H9/RTneo were readily expanded to >10 liters  over a 
period of several weeks by maintaining the ceils in log phase. 
They have remained HIV + for over 1.5 yr,  showing that 
HIV expression is compatible with long-term cell viability 
and proliferative activity, at least under special circumstances. 
H9/R7hyg, Jurkat/R7hyg, and T1/R7hyg were also main- 
tained and expanded for several months, whereas MOLT- 
4/RThyg, JY/R7hyg, and U937/R7hyg grew more slowly, 
possibly reflecting their greater susceptibility to cytopathic 
effects of the virus and the gradual emergence of variants resis- 
tant  to  these  effects.  Only  T2/RThyg  suffered  steadily 
declining viability,  and these ceils did not survive beyond a 
few months despite evidence of successful transfection and 
initial selection of an HIV + population. In light of CD4- 
dependent syncytia  formation as  a  mechanism for HIV- 
mediated cytopathicity (39), the high CD4 levels in T2 ceils 
(70-80% higher than T1 and U937, the next highest) were 
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considered a possible explanation for the singular failure of 
these cells to survive infection. However, when T2 cells were 
first  sorted  by  FACS  |  (Becton  Dickinson &  Co.)  for  a 
CD4  l~  subset (stable for at least  1 mo at a level 30-40% 
higher than T1) and then transfected, the resulting T2/K7byg 
was still only a short-term cell line. Neverthdess, these ceils 
were uniformly HW + and could be tested as targets for lysis 
by specific CTL along with the other stably transfected lines. 
Lysis of  HIV-infected  CelI Lines by HIV-specific  CTL.  HIV- 
infected cells were tested as targets for direct lysis by several 
HW-specific CD8 + CTL, including the A2-restricted gag- 
specific line 115Ip and the A2-restricted RT-specific done 
68A62. CTL line 115Ip readily lysed the A2 + HIV-infected 
target ceils JA2/RThyg, JY/K7hyg, and T1/K7hyg but not 
their untransfected counterparts (Fig. 2, A-C). CTL done 
68A62 specifically lysed target cells T1/K7hyg and JY/R7hyg 
(to a lesser extent), but JA2/R7hyg was hardly lysed more 
than uninfected  JA2 cells (Fig. 2, E-G). The fourth available 
A2 + HIV-infected target ceil, T2/K7hyg, is a mutant cell 
line lacking genes for the peptide transporter subunits TAP-1 
and TAP-2; it was not lysed by CTL 115Ip despite high levels 
of p24 expression (Fig.  2 D).  Consistent with this result, 
previous studies showed that T2 cells infected with influenza 
virus, vaccinia virus, or vesicular stomatitis virus (VSV) failed 
to present known viral epitopes to appropriate CD8 + CTL 
(40-43);  however,  these same cells were shown to present 
epitopes from Sendal virus (43), HIV-1 env (44), and minigene 
expression vectors encoding certain viral peptides (45),  ap- 
parently via a TAP-independent pathway for loading MHC-I 
molecules with cytosolic peptides. Failure to detect lysis of 
T2/R7hyg cells under conditions where T1/RThyg and other 
HIV +  ceils  were d~ciently lysed  suggests that  the TAP 
pathway is required for normal presentation of the gag pep- 
tide recognized by CTL 115Ip. 
Identification of the Optimal STnthetic Peptides  Recognized by 
Two HIV-speci.fic  CTL.  Two sets ofpeptides based on preci- 
ously described gag (33, Johnson, K. P., unpublished data) 
and KT (32, 38) sequences were synthesized and tested for 
their ability to sensitize uninfected A2 + target ceils for lysis 
by the A2-restricted CTL 115Ip and 68A62, respectively. The 
peptide with the lowest peptide concentration that sensitizes 
target cells for half-maximal lysis (SDs0) value (38), i.e., pep- 
tide concentration giving 50% of maximal specific lysis, was 
defined as the optimal synthetic peptide for each CTL. Results 
for CTL 115Ip are shown in Fig. 3 A. Peptides gag-SL9 and 
gag-RL10 were both active at picomolar concentrations, and 
gag-SL9 consistently had the lowest SDs0 (=30 pg/ml). The 
dosdy related 9-residue peptides gag-LY9 and gag-lkT9 were 
10,000-fold less active than gag-SLg, although at micromolar 
concentrations even these peptides resulted in >50% spedfic 
lysis of A2 + target ceUs. For CTL done 68A62, SDs0 data 
from the screening of 18 synthetic peptides derived from RT 
residues 469-485 were previously tabulated (38),  and some 
of the titrations are shown in Fig. 3 B. RT-IV9, the optimal 
synthetic peptide for this CTL done (SDs0 =1 pg/ml), was 
previously shown to associate tightly and specifically with 
target cell A2, dissociating with a half-life of 200-600 h (as 
its iodinated derivative). Fqptre  1.  Lymphocyte cell lines ~  with 
HW-1 DNA stably and uniformly express viral an- 
tigen while continuing to proliferate.  Cells were 
~ected  with ph~i,l R7hyg,  grown in the pres- 
ence of hygromydn B for at least 1 mo, and stained 
with anti-p24 monoclonal antibody and HTC- 
hbded secondary antibody as d~l  in Ma~zials 
and Methods. For each cell line, a single field is 
visualized  by fluorescence (/eft) and phase contrast 
(r/ght) microscopy. Cell lines shown are JA2/K7hyg 
(A and B), H9/K7hyg (C and D), T1/K7hyg (E 
and F), and JY/K7hyg (G and/-/). For H9/K7hyg 
ceils, HIV-induced syncytia can be seen. Untrans- 
feeted control cells exhibited  no fluorescence under 
the staining conditions used. 
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Figure 2.  HIV-exl~'essing  cell lines are susceptible to lysis  by HIV-specific 
CTL. Cytotoxicit  7  assays were carried out using the gag-specific CTL 
line 115Ip (A-D) or the RT-specific CTL clone 68A62  (E-G) and the 
slCr-labeled target cells indicated at the top of each panel. Lysis of T2 
cells by CTL clone 68A62 was not tested. Target cells were either untTans- 
fected (O) or had been transfected with plasmid K7hyg at least 1 mo be- 
fore and were uniformly positive for HIV expression by p24 immunofluores- 
cence (O). In addition, the Bw62-restricted gag-specific CTL lines 35C18 
and 35C44, obtained by stimulating PBMC from an HIV-l-seropositive 
individual  with  the  25-residue  peptide  p17/2  (33),  etficiently lysed 
Hg/K7hyg cells but not untransfected H9 cells (not shown). 
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Figure 3.  Synthetic peptides define the optimal epitopes recognized by 
HI'V-specific CTL. Cytotuxicity assays were carried out with (.4) the gag- 
specific CTL line 115Ip and slCr-labeled autologous 115EBV target cells 
or (B) the RT-specific CTL clone 68A62 and stCr-labeled  JY target ceils. 
Various concentrations of the synthetic peptides shown were added to target 
cells for 1 h at 37~  and remained in the assay during the 4-h incubation 
of CTL and target ceils. Cells were then pelleted and supernatants were 
assayed for StCr release. All peptides were negative for toxicity (<5% 
specific lysis) and were titrated at least twice, with results always within 
one order of magnitude. Also tested with CTL 115Ip, but not shown, 
were gag peptides LL8, RTg, and ST8, each of which was less active than 
gag-LY9.  SDs0 values (peptide concentrations giving 50%  of maximal 
specific lysis [38]) for the optimally active synthetic peptides gag-SL9 (A) 
and RT-IV9 (B) were 30 pg/ml and 1 pg/ml, respectively. 
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Figure 4.  HIV-expressing cell line JA2/R7hyg produces a single pep- 
tide, gag-SL9, for recognition by CTL line 115Ip. (A) 109 JA2/R7hyg 
(0) or untransfected JA2 (O) cells were lysed in 1% TFA, homogenized 
by douncing,  subjected to ultrafiitration in order to isohte a peptide- 
COOtlln;n~ fraction (<10 kD), and fractionated by C18 HPLC using a gra- 
dient of 0.25% isopropanol per min at a flow rate of 1 ml/min. Fractions 
were collected at 1 min intervals, dried, and tested for their ability to sen- 
sitize StCr-hbded 115EBV target cells for iysis by CTL 115Ip in a 4-h 
cytotoxidty assay. Toxicity controls consisting of target cells incubated 
with each fraction in the absence of CTL were negative (not shown). (B) 
HPLC retention times of the synthetic peptides that can be recognized 
by CTL 115Ip are shown under the same chromatographic conditions used 
in A. In addition, gag peptides ST8 and RT9 both duted in fraction 19, 
which  does not correspond to  an  active  fraction from TFA-extracted 
JA2/R7hyg cells. 
Identification of Two 1-111/-1 Peptides Produced by Endogenous 
Antigen Processing in Infected Cells.  To identify the naturally 
processed HIV-1  peptides present  in  HIV-infected cells, 
JA2/R7hyg cells were expanded to several liters, and MHC- 
bound peptides were isolated by TFA extraction, ultrafaltra- 
tion, and reverse phase HPLC fractionation. When the HPLC 
fractions were added to uninfected A2 + target cells in cyto- 
toxicity assays, only a single HPLC fraction had sensitizing 
activity for each of the two A2-restricted HIV-specific CTL 
examined: fraction 41 for CTL 115Ip (Fig. 4 A) and fraction 
32 for CTL 68A62 (Fig.  5 A). 
To identify the active peptides in these fractions, their reten- 
tion times were compared with those of all the synthetic pep- 
tides that could be recognized by the same CTL. Under an 
appropriate set of HPLC conditions (column, solvents, gra- 
dient, etc.), peptides differing even slightly in length or se- 
quence can be resolved and therefore differentiated based on 
characteristic retention times. Thus, ofaU the active synthetic 
gag peptides tested using CTL 115Ip (including all possible 
8-, 9-, and 10-reefs contained within a longer active syn- 
thetic peptide), only gag-SL9 eluted in fraction 41 under the 
same HPLC conditions used for the JA2/R7hyg cell extract 
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Figure  5,  HIV-expressing cell lineJA2/RThyg produces a single pep- 
tide, KT-IV9, for recognition by CTL 68A62. (,4) 109 JA2/KThyg cells 
were lysed in 1% TFA and prepared as described in Fig. 4 A, mcept that 
HPI,C fractionation was performed using a gradient of 1% acetonitrile 
per min. Fractions were added to stCr-hbeled JY target cells and tested 
for toxicity (A) and for lysis by CTL 68A62  (O). (/3) HPI,  C  retention 
times of the synthetic peptides that can be recognized by CTL 68A62 
are shown under the same chromatographic conditions used in A. 
(Fig. 4 B), indicating that the peptide recognized by CTL 
115Ip on the surface of HIV-infected cells is gag-SL9. Simi- 
larly for CTL 68A62, only synthetic peptide RT-IV9 had 
the same retention time as the active HPLC fraction isolated 
from JA2/R7hyg cells (Fig. 5 B), indicating that CTL 68A62 
recognizes RT-IV9 on HIV-infected cells. 
The Abundance  of Two Naturally  Processed  HIV-I Pep￿9  To 
measure the abundance of the naturally processed peptide gag- 
SL9,  10  9 JA2/R7hyg  cells were lysed  and treated as  de- 
scribed above, and the active HPLC fraction was titrated in 
a cytotoxicity assay using CTL 115Ip. As shown in Hg. 6 
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Figure 6.  EachJA2/K7hyg cell contains apprmfmately 400 molecules 
of peptide gag-SL9. (A) 109 JA2/R7byg cells were lysed in 1% TF^ and 
prepared as described in Fig. 4 A. The active I-IPLC fraction recognized 
by CTL 115Ip was titzated in a standard cytotoxidty assay using slCr- 
labeled JY target cells. Percent specific lysis values obtained using 107 or 
10  s JA2/RTbyg cell equivalents per well (Le., I or 10% of the active frac- 
tion) are indicated by arrows on a standard curve performed with syn- 
thetic peptide gag-SL9 and JY target cells in the same assay. The calcu- 
lated recovery was ,~100 gag-SL9 molecules lX~ JA2/R7hyg cell. (B) 109 
untransfected JA2 cells were ly,.ed as de~'ibed (o/nn circles)  or were tit 
"spiked" with 100 pg synthetic gag-SL9 (solid trian&les) or 1 ng gag-RL10 
(solid squares). From a comparison of percent specific lysis values due to 
TFA-extracted cells and standard curves for each of these synthetic pep- 
tides, their overall yields for all steps from cell lysis through cytotoxicity 
assay were found to be 25 and 30%, respectively. 
A,  the  amount  of  peptide  recovered  from  107  or  10  s 
JA2/R7byg cells gave 19 or 50% specific lysis, respectively. 
These values, compared with the standard curve from a cyto- 
toxicity assay carried out under identical conditions with syn- 
thetic gag-SL9, correspond to a recovery of ~'100 peptide mol- 
ecules per JA2/R7hyg cell. To estimate the overall efficiency 
of peptide recovery, a "spiking" experiment was performed 
in which 100 pg synthetic gag-SL9  was added to 109 un- 
transfected JA2 cells. Subsequent extraction and fractionation 
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minating in cytotoxicity assay of HPLC fractions using CTL 
115Ip (Pig. 6 B). From the percent specific lysis due to either 
5 or 20% of the sample in fraction 42 (5 pg or 20 pg if the 
overall yield was 100%), comparison to a standard curve for 
synthetic gag-SL9 led to an estimated 25% oven11 yidd (e.g., 
20% of the sample gave 33%  specific lysis, corresponding 
to 5 pg synthetic gag-SL9 on a standard curve generated in 
the same assay; standard curve not shown). Similarly, for syn- 
thetic gag-RL10 added to untransfectedJA2 ceils, the overall 
yield was 30%. Since even a very tightly A2-binding peptide 
(radiolabded RT-IV9) completely dissociated from A2 after 
60 min of exposure to  1%  TFA (38),  the calculated yield 
likely reflects all steps in the isolation of naturally processed 
gag-SL9, including the release of peptide from preexisting 
peptide--MHC complexes. 
The abundance of naturally processed peptide RT-IV9 was 
established similarly by comparison with a standard curve 
of synthetic RT-IV9. The amount of peptide recovered from 
2  x  10  s JA2/RThyg ceils gave the same degree of lysis as 
6  x  10  s molecules of synthetic RT-IV9  when added to 
uninfected A2 + target ceils (i.e., a synthetic peptide concen- 
tration of 5  x  10-t2 M  in a total volume of 200 ~1; not 
shown). Therefore only =3 molecules of RT-W9 per HIV- 
infected cell were recovered, for a calculated abundance of 
=12 molecules per infected cell (assuming a similar overall 
yield to gag-SL9 and gag-RL10). 
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Figure 7.  Generation  ofpeptidr gag-SL9  in HIV-cxpressing  cells  is in- 
dependent  of  HLA-A2.  JA2/R7hyg cells (solid  dmles), H9/R7neo  cells  (solid 
tr/a,g/es), or untransfected  JA2 cells (solid  squares)  were lysed  in 1% TFA 
end prepared  as described  in lqig. 4 A. Fractions  were  tested  for thdr ability 
to sensitize slCr-hbelcd 115EBV target calls for lysis by CTL 115Ip in 
a 4-h cytotoxia't-y  assay.  Toxicity  controh  consisting  of  target  ~  incubated 
with each  fraction  in the absence  of  CTL are included  (corresposding  empty 
symboh).  H9/R7neo cells are HLA-A2-. Ret~tion time of the active  frac- 
tion does  not agree  pmcisdy  with Fig. 4 A because  a different  C18 column 
was used for this separation. Untramfected  JA2 cells fractionated  before 
H9/K7nco gave  no activity,  ruling  out contamination  of  the HPLC  cohtmn. 
Expression of an HLA-A2-binding HIV-I Peptide Occurs In- 
dependently of  HLA.AZ  Given numerous findings by Ram- 
mensee et al. (46) that peptides recognized by CTL accumu- 
late to detectable levels only in ceils expressing the restricting 
MHC molecule, we were surprised to find a strong peak of 
activity corresponding to gag-SL9 in TFA extracts of the 
A2-  infected cell line H9/R7neo (Fig.  7). However, it re- 
mains unknown whether gag-SL9 binds to a different HLA 
molecule expressed by H9 cells, e.g., HLA-A1, Bw62, or Cw6. 
Discussion 
The reasons for incomplete elimination of HIV-infected 
ceils by CTL in vivo are not yet understood (20, 21).  One 
possibility is that high mutation rates in viral proteins could 
impair recognition and lysis of infected cells by virus-specific 
CTL (22), much as mutations in viral surface glycoproteins 
can result in escape from antibody recognition (47). To date, 
evidence both for and against the emergence of CTL escape 
mutants in HIV infection has been published (23,  24,  48, 
49).  Another mechanism for diminished CD8 +  CTL  ac- 
tivity in HIV infection may be altered lymphokine produc- 
tion by "helper"  T  cells  as  a  result  of steadily declining 
CD4 + T  cell counts and aberrant CD4 + T  cell function 
in inf~ed  individuals.  However,  some  individuals  with 
low CD4 + T  cell levels retain vigorous CTL activity (50); 
furthermore, intact CD8 + CTL function in CD4-deficient 
"knockout" mice argues against an absolute dependence of 
CTL on CD4 + T  ceils  (51).  Here we raise  a third possi- 
bility: CTL of HIV-infected individuals may be incompletdy 
effective in eradicating the virus because of a paucity of viral 
epitopes expressed on infected cells. 
When ceils are infected by lyric viruses (including influenza, 
vaccinia, Sendal, and VSV), host ceU protein synthesis shifts 
toward virus-encoded products at the expense of endogenous 
("sdf") protein synthesis. This overproduction of viral pro- 
teins gives rise to relatively high levels of viral peptides, which 
in turn form high ceil surface densities of peptide-MHC-I 
complexes and facilitate lysis of the infected cells by virus- 
specific  CTL.  Accordingly, previous  studies  of naturally 
processed viral peptides seen by T calls have made use of lyti- 
call)" infected ceils (52-54). However, infection by HIV (or 
by certain other viruses, such as EBV and CMV) can result 
in chronic expression of viral proteins for months or years, 
along with the full complement of normal sdf proteins neces- 
sary for ceil viability and function. In these cases, a rdatively 
small number of viral proteins (i.e., =10 for HI'V) must com- 
pete with all the proteins normally expressed in a ceil (per- 
haps 5,000-10,000) for presentation by a limited number of 
MHC-I proteins to CD8 + T  ceils.  Can HIV-derived pep- 
tides compete with such a vast excess of self peptides and 
occupy sufficient numbers of MHC-I binding sites to result 
in effective killing of HIV-infected ceils by CTL? 
Previous studies of peptides recognized by HIV-specific T 
ceils have relied on vaccinia virus recombinants containing 
HIV genes or gene segments and synthetic peptides corre- 
sponding to HIV sequences (27,  28).  While these studies 
have led to the delineation of numerous T cell epitopes, oper- 
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tivities in vitro, and to the identification of candidate pep- 
tides for vaccine trials (55), little is known about which of 
these peptides are actually generated within HW-infected cells, 
their respective abundances, or their likely importance in the 
anti-HIV CTL response. 
To reveal the identities and abundances of HIV-1 peptides 
expressed by infected cells and recognized by HI'V-specific 
CTL, we developed a panel of stably HIV-infected cell lines 
from which naturally processed peptides could be isolated 
directly. Adding infectious HIV-1 directly to CD4 + cells as 
a method of establishing infection tends to result in cultures 
which are only partially infected and which are dil]~cult to 
sustain, presumably due to cytopathic effects of the virus. 
Therefore to obtain cultures in which all of the ceils are produc- 
tivdy infected and can be expanded to large numbers, we 
introduced the viral genome by transfection of doned proviral 
DNA containing the entire HIV-1 genome except for nef, 
which is not required for viral replication in cell culture and 
which was replaced by an antibiotic resistance gene (neomycin 
or hygromycin) (35). Cell cultures under continuous antibi- 
otic selection were uniformly HIV § (Fig.  1) and were ex- 
panded to many liters while continuing to express HIV for 
long periods (over 1.5 yr for JA2/R7hyg and H9/R7neo). 
Establishment of the infected B cell line JY/K7hyg, CD4- 
by flow cytometry, was also made possible by this technique 
of transfection and direct sdection. Other HIV-infected A2- 
negative cell lines have previously been established  for var- 
ious studies, indnding derivatives of A3.01, H9, Hela-T4 +, 
and U937 cells (56). 
The  KT-specitic  CTL  clone  68A62  lysed  cell  lines 
T1/K7hyg and JY/K7hyg reasonably well, but hardly lysed 
JA2/R7hyg even at a CTL/target cell ratio of 50:1. Since 
JA2/K7hyg was lysed well by CTL 115Ip, these results sug- 
gested that levels of the naturally processed peptide(s) seen 
by 68?,62 may be low on JA2/K7hyg cells. To address this 
issue directly, we applied techniques described by Rammeusee 
et al. (46) to determine the precise identity and abundance 
of this naturally processed peptide(s). Briefly, HlV-infected 
target cells were treated with TFA, the extracted peptides 
were fractionated by reverse phase HPLC, and individual frac- 
tions were added to uninfected A2 + cells for cytotoxidty 
assay. Because the naturally processed peptides from, say, 10  s 
cells can be loaded onto 104 A2 + target cells in a cytotox- 
idty assay, the sensitivity of peptide detection is amplified 
by as much as 10,000-fold  (or even more if more cells are 
~tracted, subject m solubility and toxicity limitations). An- 
other advantage of this assay system is that both A2 § and 
A2- infected cells can be examined for the presence of a par- 
ticnlar peptide, since A2 + target cells are used in the final 
assay(e.g., Fig. 7). Because the retmtion time of a given peptide 
under well-defined I-IPLC conditions is highly ~producible, 
comparison with synthetic peptide standards allows the nat- 
urally processed peptide(s) to be identified and qnantitated. 
(In contrast, the amount of peptide recovered from 105-101~ 
cells is typically in the low or ~tomole  range, well bdow 
what is usually required for direct chemical sequencing by 
Edman degradation or mass spectrometry.) By these methods 
it was established that the single naturally procx~sed peptides 
recognized by CTL 1151p and 68A62 were geg-SL9 and RT- 
IV9, respectively (Figs. 3-5). Both peptides matched the op- 
timally active synthetic peptides recognized by these CTL, 
and both conform to the A2 consensus motif (57). 
The abundance of naturally processed gag-SL9 was found 
to be ~  molecules per infected cell by measuring the 
recovery of this peptide from JA2/K7byg cells (=100 mole- 
cules/cell) and the efflcieucy of the isolation procedure (25%) 
(Fig. 6).  Assuming that half the losses are associated with 
the HPLC step (50% yield), repeated rounds of I-IPI.C frac- 
tionation will result in much more severe losse~ FOr example, 
the purification of two overlapping peptides from the en- 
zyme a-ketoghtarate dehydmgenase that are recognized by 
an alloreactive CTL done was accomplished by five (58) or 
six (59) successive HPLC rounds before sequencing; if each 
round was associated with a 50% yield, the cumulative yidd 
would have been only 1-3%.  In this scenario,  the natural 
abundance of these two peptides is far greater than that of 
HIV-1 mS lX-taide  a ce =400 (S8)  7,000 
(59) peptide molecules per allogeneic cell were actually re- 
covered, their abundances are likely to be as high as 12,000 
and 400,000 molecules per cell, allowing for the expected 
yidds. Such high abundances of naturally processed peptides 
in the alloreactive system may result from high levels of their 
precursor,  a normal cell protein, and probably account for 
the appearance of a family of IX'prides rather than the single 
pept   by two HIV-   (as wall 
[52-541) CTL 
The extent oflysis by CTL 115Ip (as much as 80% specific 
lysis of  JY/R7byg target cells) indicates that HIV-1 peptides 
can compete with the myriad self peptides generated in the 
same cells for binding to MHC-I proteins and transport to 
the cell surface. In fact, the levels of gag peptide (=400 mol- 
ecules per infected cell) were not much lower than the recov- 
eries of two influenza peptides from influenza virus-inkoed 
cens (2 -54o  mdw,l cen,  unmnmed for extraction 
des [60]), despite the significantly diffenmt nature of the two 
infections (lytic vs. chronic). For VSV-infecud cells, however, 
van Bleek and Nath,m~n reported that 5-10% of MHC-bound 
peptides were of viral origin, and that these were dominated 
by a  omm   a  Ugh  
in this system (52). A naturally processed L/aer/a moaacytogenes 
peptide epitope similarly was _Wese-__t  at >3,000 copies per in- 
fected cell (61). But in cells ~  with the ovalbnmin 
genc and recognized by ovalbumin-specific CTL, only =100 
molecules of a semiti~ng ovalbumin peptide were recovered 
(no correction for extractiun etfiden~) (62). 
In contrast to CTL 115Ip, CTL 68A62 exhibited lower 
levels of activity against HIV-infected target cells, and lysed 
JA2/RTbyg only poorly even though the optimally active 
peptide RT-IV9 was shown to be present in these same cells. 
This result can be explained  by the relatively low abu~adance 
of RT-IV9 on JA2/gThyg cells (=12 molecules per cdl), con- 
sistent with the 10--20-fold lower expression Of RT than gag 
protein in HIV-infected ceils due m a ribosomal frameshift 
required for RT exptmdon (63). Since growth of  JA2/R7hyg 
cells under sdective pressure for HIV expression might have 
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IV9 could be even more sparse on naturally infected calls. 
T1/R7hyg cells, which are lysed better than JA2/R7hyg cells 
by CTL 68A62, probably have a higher epitope density, as 
suggested by higher levels of p24 antigen (not shown) and 
by the fact that uninfected T1 and JA2 cells are similarly sen- 
sitive to exogenous RT-IV9 (SDs0 =  10-20 pg/ml). Thus, 
in spite of the extreme sensitivity of CTL 68A62 to synthetic 
RT-IV9 (Fig.  3 B) and the demonstration of RT-IV9 in 
JA2/R7hyg  call  extracts  (Fig.  5),  CTL  68A62  lyses 
JA2/R7hyg ceils indfidently (rdative to their lysis by CTL 
115Ip, Fig. 2), emphasizing the critical role of epitope den- 
sity in lysis of these infected target cells and raising a serious 
question as to the likely effectiveness  of this CTL done in vivo. 
In this context it is worth noting that when synthetic pep- 
tides are added to target cells in cytott~ddty assays, very high 
peptide concentrations are often used, e.g., 10-100/~M. At 
such concentrations, peptides with even modest affinities for 
the restricting  MHC molecule (K^  =  106-10  s M-I) will oc- 
cupy a large fraction of available MHC binding sites at equi- 
librium (>99%), resulting in far greater numbers of spedfic 
peptide-MHC complexes than the few hundred per cell often 
seen for naturally processed peptides (53,  60, 62, 64).  For 
enmple, JY calls have =10,000 A2 molecules available for 
binding to exogenous Ix-prides 08), so peptide RT-IV9 (equi- 
librium constant for binding to A2 =107 M-~ [I~geyama 
et al., manuscript submitted for puhlication]) will form up 
to 10,000 peptide-MHC complea~s per target ceU when added 
at micromolar concentrations. Similarly, other synthetic pep- 
tides can dficiently sensitize target ceils by loading cell sur- 
face MHC-I molecules even though these peptides are not 
detectable in infected cells and are therefore not actually rele- 
vant to the immune response (e.g.,  gag-RL10, RT-EV10). 
Thus epitope identification based on synthetic peptideg while 
useful as a preliminary guide, may not accuratdy represent 
CTL-target cell interactions as they occur in vivo. 
Overall, our results suggest that HIV-infected ceils can 
be good targets for lysis by HIV-specitic CTL, but that CTL 
effectiveness depends critically upon epitope density: the KT- 
specific done 68A62 exhibited poor killing of a target cell 
(JA2/RThyg) that was shown to express only a few copies 
per cell of the optimally active peptide. Because the affanities 
of antigen-specific  T  cell receptors for their peptide-MHC 
ligands are likely to influence the density of epitopes required 
for etfident lysis of target cells, it is still possible that CTL 
bearing high-affanity receptors may lyse infected target cells 
having very low epitope densities (Kageyama et al.,  manu- 
script submitted for publication; and Sykulev et al. [64a]); 
however, no information is currently available regarding T 
cell receptor affnfities for HIV-specflic CTL. The outcomes 
of adoptive therapy trials ~ing CTL in HIV-infected humans 
(65, 66) may therefore depend on T  cell receptor affinities 
as well as on the numbers and specflidties of the CTL used. 
The most effective CTL againgt HIV-infe~ed cells ultimately 
may be those that can recognize the most abundant natu- 
rally processed HIV epitopes; using the stably infected cell 
lines described here, it should be possible to identify and quan- 
titate these epitopes. 
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